Anika Therapeutics, Inc.

ANIK Nasdaq SEC CIK 898437
Follow Anika Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $30.6M +10% vs same quarter last year
Net income −$311K +86.6% vs same quarter last year
EPS, diluted −$0.02 +87.5% vs same quarter last year
Operating cash flow $8.4M +21.9% vs same quarter last year
Revenue by quarter
$30.6M
$26.2M
$28.2M
$27.8M
$30.6M
$29.6M
$32.6M
$30.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$100M$0$100M$200MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$112.8M−$11M
FY24$119.9M−$56M
FY23$120.8M−$83M
FY22$113.8M−$15M
FY21$147.8M$4M
FY20$130.5M−$24M
FY19$114.6M$27.2M
FY18$105.6M$18.7M
FY17$113.4M$31.8M
FY16$103.4M$32.5M
FY15$93M$30.8M
FY14$105.6M$38.3M
FY13$75.1M$20.6M
FY12$71.4M$11.8M
FY11$64.8M$8.5M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−100%−50%0%50%100%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2556.6%−9.8%−9.8%
FY2463.4%−4.3%−46.7%
FY2368.3%0.7%−68.7%
FY2264.3%3.2%−13.2%
FY2156.1%1.8%2.7%
FY2052.9%−21.7%−18.4%
FY1974.9%29.9%23.7%
FY1870.4%20.6%17.7%
FY1775.9%40.3%28.1%
FY1676.8%49%31.5%
FY1577.4%51.8%33.1%
FY1480.2%58.2%36.3%
FY1369.7%43.4%27.4%
FY1259.4%27.6%16.5%
FY1158.7%21.6%13.1%
Free cash flowOperating cash flow minus capital expenditure
−$20M$0$20M$40MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$4.4M
FY24−$2.3M
FY23−$7.2M
FY22−$3.1M
FY21$3.3M
FY20$11.4M
FY19$34.2M
FY18$30.3M
FY17$31.8M
FY16$10.4M
FY15$30.7M
FY14$38.4M
FY13$24.7M
FY12$9M
FY11$8.8M
Returned to shareholdersDividends paid and shares bought back
$0$10M$20M$30MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25$9.5M
FY24$10.9M
FY23$5M
FY22$0
FY21$0
FY20$0
FY19$30M
FY18$30M
FY17-
FY16$25M
FY15-
FY14-
FY13-
FY12-
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Anika Therapeutics
  • Healthcare median
−100%−50%0%50%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearAnika TherapeuticsHealthcare median
FY25−9.8%−30.6%
FY24−46.7%−47%
FY23−68.7%−58%
FY22−13.2%−80.4%
FY212.7%−71.9%
FY20−18.4%−62.2%
FY1923.7%−46.3%
FY1817.7%−49.6%
FY1728.1%−45.9%
FY1631.5%−36%
FY1533.1%−38.4%
FY1436.3%−35.5%
FY1327.4%−37.1%
FY1216.5%−29.1%
FY1113.1%−27.9%